奥德维克西巴特改善了阿拉吉尔综合征中的和胆酸水平:一个病例报告
1Division of Pediatric Gastroenterology, Sheikh Khalifa Medical City, Abu Dhabi 51900, United Arab Emirates.
World journal of gastrointestinal pharmacology and therapeutics
|September 12, 2025
概括
奥德维克西巴特有效地治疗了阿拉吉尔综合征患者的难治性,改善了生活质量和肝酶. 这种以利亚胆汁酸载体抑制剂显示,在儿科胆固醇性肝病中,有可能延迟肝移植.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 遗传学 遗传学 是一个
- 儿科胃肠病学 儿科胃肠病学
背景情况:
- 阿拉吉尔综合征 (ALGS) 是一种罕见的遗传疾病,导致胆固醇,黄和严重的,显著影响生活质量 (QoL).
- 目前的ALGS肝脏管理是支持性的,往往导致肝移植.
- 皮质胆酸载体 (IBAT) 抑制为胆固醇性和肝病提供了一种新的治疗策略.
研究的目的:
- 报告一家患有阿拉吉尔综合征的儿科病人的IBAT抑制剂odevixibat的12个月效果.
- 评估奥德维克西巴特对ALGS难治性,肝功能和QoL的影响.
主要方法:
- 一名被诊断患有ALGS (JAG1突变) 的男性婴儿,尽管接受了标准治疗 (ursodiol,rifampin,cholestyramine,cetirizine),但出现了严重的.
- 开始使用奥德维克西巴特,并定位至120μg/kg/天.
- 在12个月内监测了临床结果,包括,睡眠,肝酶,胆红素,胆汁酸和QoL.
主要成果:
- 奥德维克西巴特迅速改善了,首次使人能够过夜睡觉.
- 在12个月的时间里,血清胆汁酸,胆红素和氨酸转移酶水平显著改善.
- 在治疗期间没有报告任何不良副作用.
结论:
- 这一案例突显了像odevixibat这样的IBAT抑制剂在治疗ALGS患者的和增强QOL方面的有效性.
- 奥德维克西巴特可能有潜力推迟在ALGS中需要进行肝移植.
- 需要进一步的长期研究,以充分阐明IBAT抑制剂在儿科胆固醇性肝病中的益处.
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
636
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
636
Inflammatory Bowel Disease IV: Pharmacological Management
531
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
531
Drugs for Treatment of Ulcerative Colitis in IBD
463
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
463
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
644
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
644
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
736
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
736
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
495
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
495


